Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00436280
Status:
COMPLETED
Last Update Posted:
2020-08-06
First Post:
2007-02-16
Brief Title:
Chemotherapy for Participants With Lymphoma
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
An Open-label Single Arm Phase 2 Study of Rituximab Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to help answer the following research questions
To assess whether Enzastaurin combined with rituximab gemcitabine and oxaliplatin R-GEMOX can help participants with Diffuse Large B-Cell Lymphoma DLBCL remain free from disease and thus live longer
To assess for any side effects that might be associated with enzastaurin and R-GEMOX
To look at the characteristics and levels of certain genes and proteins to learn more about DLBCL and how enzastaurin works in the body
To look at the level of enzastaurin in the body and how long it remains
To assess whether Enzastaurin combined with rituximab gemcitabine and oxaliplatin R-GEMOX can help participants with Diffuse Large B-Cell Lymphoma DLBCL remain free from disease and thus live longer
To assess for any side effects that might be associated with enzastaurin and R-GEMOX
To look at the characteristics and levels of certain genes and proteins to learn more about DLBCL and how enzastaurin works in the body
To look at the level of enzastaurin in the body and how long it remains
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H6Q-MC-S013 | OTHER | Eli Lilly and Company | None |